Ken Griffin Intra Cellular Therapies, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 40,500 shares of ITCI stock, worth $3.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,500

Previous 61,300 33.93%

Holding current value

$3.45 Million

Previous $4.2 Million 29.47%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$64.76 - $79.84 $14.7 Million - $18.2 Million	-227,621 Reduced 63.0%	133,673 $9.16 Million
Q1 2024 May 15, 2024	BUY	$64.37 - $75.65 $21 Million - $24.6 Million	325,722 Added 915.67%	361,294 $25 Million
Q4 2023 Feb 14, 2024	SELL	$46.37 - $73.65 $2.3 Million - $3.65 Million	-49,610 Reduced 58.24%	35,572 $2.55 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $3.18 Million - $3.92 Million	61,089 Added 253.55%	85,182 $4.44 Million
Q2 2023 Aug 14, 2023	SELL	$54.67 - $66.44 $32.2 Million - $39.2 Million	-589,663 Reduced 96.07%	24,093 $1.53 Million
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $2.11 Million - $2.74 Million	-48,107 Reduced 7.27%	613,756 $33.2 Million
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $21 Million - $26 Million	477,231 Added 258.48%	661,863 $35 Million
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $9.44 Million - $13.3 Million	-221,099 Reduced 54.49%	184,632 $8.59 Million
Q2 2022 Aug 15, 2022	SELL	$43.0 - $65.64 $8.31 Million - $12.7 Million	-193,301 Reduced 32.27%	405,731 $23.2 Million
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $5.88 Million - $9.42 Million	-151,684 Reduced 20.21%	599,032 $36.7 Million
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $15 Million - $22.7 Million	-425,749 Reduced 36.19%	750,716 $39.3 Million
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $11.1 Million - $16.4 Million	-384,927 Reduced 24.65%	1,176,465 $43.9 Million
Q2 2021 Aug 16, 2021	BUY	$29.3 - $44.5 $1.92 Million - $2.91 Million	65,386 Added 4.37%	1,561,392 $63.7 Million
Q1 2021 May 17, 2021	BUY	$30.8 - $39.51 $2.17 Million - $2.78 Million	70,320 Added 4.93%	1,496,006 $50.8 Million
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $7.99 Million - $11 Million	342,124 Added 31.57%	1,425,686 $45.3 Million
Q3 2020 Nov 16, 2020	BUY	$17.61 - $31.86 $10.2 Million - $18.5 Million	582,002 Added 116.04%	1,083,562 $27.8 Million
Q2 2020 Aug 14, 2020	BUY	$14.35 - $26.64 $3.48 Million - $6.45 Million	242,173 Added 93.36%	501,560 $12.9 Million
Q1 2020 May 15, 2020	SELL	$12.31 - $33.12 $4.45 Million - $12 Million	-361,527 Reduced 58.22%	259,387 $3.99 Million
Q4 2019 Feb 14, 2020	SELL	$7.26 - $38.49 $620,054 - $3.29 Million	-85,407 Reduced 12.09%	620,914 $21.3 Million
Q3 2019 Nov 14, 2019	BUY	$7.47 - $14.03 $2.74 Million - $5.14 Million	366,673 Added 107.96%	706,321 $5.28 Million
Q2 2019 Aug 14, 2019	BUY	$10.65 - $14.29 $2.63 Million - $3.53 Million	246,976 Added 266.51%	339,648 $4.41 Million
Q1 2019 May 15, 2019	SELL	$10.9 - $14.09 $10.4 Million - $13.5 Million	-955,461 Reduced 91.16%	92,672 $0
Q4 2018 Feb 14, 2019	BUY	$10.36 - $20.96 $2.8 Million - $5.66 Million	269,940 Added 34.69%	1,048,133 $11.9 Million
Q3 2018 Nov 13, 2018	SELL	$17.77 - $22.9 $9.66 Million - $12.4 Million	-543,531 Reduced 41.12%	778,193 $0
Q2 2018 Aug 10, 2018	BUY	$17.33 - $23.4 $2.9 Million - $3.91 Million	167,197 Added 14.48%	1,321,724 $0
Q1 2018 May 11, 2018	BUY	$15.16 - $25.49 $14.7 Million - $24.8 Million	972,589 Added 534.57%	1,154,527 $24.3 Million
Q4 2017 Feb 09, 2018	BUY	$14.27 - $16.79 $1.64 Million - $1.92 Million	114,606 Added 170.21%	181,938 $2.63 Million
Q3 2017 Nov 09, 2017	BUY	$10.77 - $22.1 $725,165 - $1.49 Million	67,332	67,332 $1.06 Million

Others Institutions Holding ITCI

# of Institutions

377

Shares Held

84.1M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.05B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account